Title |
CDK9 inhibitors in acute myeloid leukemia
|
---|---|
Published in |
Journal of Experimental & Clinical Cancer Research, February 2018
|
DOI | 10.1186/s13046-018-0704-8 |
Pubmed ID | |
Authors |
Silvia Boffo, Angela Damato, Luigi Alfano, Antonio Giordano |
Abstract |
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 2 | 50% |
United States | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 50% |
Members of the public | 1 | 25% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 102 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 16 | 16% |
Student > Bachelor | 13 | 13% |
Researcher | 11 | 11% |
Student > Master | 10 | 10% |
Other | 8 | 8% |
Other | 13 | 13% |
Unknown | 31 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 24 | 24% |
Medicine and Dentistry | 15 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
Chemistry | 6 | 6% |
Agricultural and Biological Sciences | 5 | 5% |
Other | 13 | 13% |
Unknown | 30 | 29% |